Codexis, Inc.

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
2.83 USD +1.07% Intraday chart for Codexis, Inc. -1.39% -7.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board CI
Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9 MT
Transcript : Codexis, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (CDXS) CODEXIS Reports Q4 Revenue $26.6M, vs. Street Est of $18.9M MT
Codexis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Codexis Shares Up 31% on Roche Licensing Agreement DJ
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche CI
Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory Board CI
Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of Director CI
Transcript : Codexis, Inc. - Special Call
Codexis, Inc. Enters into Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP CI
Codexis, Inc. announced that it expects to receive $40 million in funding CI
SeqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting CI
Swiss Shares Decline Amid Lingering Concerns for Growth of Local Economy MT
Nestlé Unit to Buy Codexis’ Pancreatic Condition Therapy for Up to $45 Million MT
Codexis, Inc. Announces Purchase Agreement with Nestle Health Science for Cdx-7108 CI
Codexis Assigns Interests in Potential Exocrine Pancreatic Insufficiency Treatment to Nestle Health Science MT
Codexis, Inc.(NasdaqGS:CDXS) dropped from NASDAQ Biotechnology Index CI
Top Midday Gainers MT
Federal Reserve Outlook Pushes Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday MT
Codexis Signs Exclusive License Agreement With Aldevron for Codex HiCap RNA Polymerase; Shares Surge Premarket MT
Codexis Signs Exclusive License Agreement With Aldevron for Codex HiCap RNA Polymerase MT
Codexis, Inc. and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase CI
Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc.. CI
Transcript : Codexis, Inc. - Special Call
Chart Codexis, Inc.
More charts
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.83 USD
Average target price
6.571 USD
Spread / Average Target
+132.21%
Consensus